碳酸氢钠治疗严重代谢性酸血症合并急性肾损伤:BICARICU-2随机临床试验
BICARICU-2是在法国43个ICU开展的随机、开放标签临床试验,纳入640例严重代谢性酸血症(pH≤7.20)合并中重度急性肾损伤的成人患者,1:1随机接受静脉碳酸氢钠输注(目标动脉pH≥7.30)或不使用碳酸氢钠。主要终点90天全因死亡率在碳酸氢钠组为62.1%(195/314),对照组为61.7%(193/313),绝对差异0.4%(95%CI -7.2至8.0,P=0.91)。28天和180天全因死亡率均无组间效应证据。肾脏替代治疗使用率碳酸氢钠组35%(109/314)低于对照组50%(157/313),绝对差异-15.5%(95%CI -23.1至-7.8)。作者结论认为,对该人群静脉碳酸氢钠不影响死亡率。
要点
- 严重代谢性酸血症(pH≤7.20)合并中重度急性肾损伤患者,碳酸氢钠组90天全因死亡率62.1% vs 对照组61.7%,绝对差异0.4%(95%CI -7.2至8.0,P=0.91)。
- 肾脏替代治疗使用率碳酸氢钠组35%(109/314)vs 对照组50%(157/313),绝对差异-15.5%(95%CI -23.1至-7.8)。
- 28天和180天全因死亡率均无组间效应证据。
- 18项次要结局中,除肾脏替代治疗外,其他次要结局(包括不良事件)均无组间效应证据。
- 干预目标为动脉pH≥7.30,静脉途径给予碳酸氢钠。
适用人群与场景
- 成人严重代谢性酸血症(定义:pH≤7.20)合并中重度急性肾损伤,收治于ICU。
诊断标准与关键阈值
- 严重代谢性酸血症诊断标准:pH≤7.20。
- 合并中重度急性肾损伤。
- 干预目标:动脉pH≥7.30。
处置流程与药物剂量
- 随机1:1接受静脉碳酸氢钠输注或不使用碳酸氢钠,目标动脉pH≥7.30。
研究设计与关键结果
- 随机、开放标签临床试验,法国43个ICU,2019年10月6日至2023年12月19日纳入640例,90天随访,末次随访2024年6月17日。
- 627例纳入分析:对照组313例,碳酸氢钠组314例;中位年龄67岁(IQR 59-74岁);碳酸氢钠组男性194/314(62%),对照组男性185/313(59%)。
- 主要终点90天全因死亡率:碳酸氢钠组195/314(62.1%)vs 对照组193/313(61.7%),绝对差异0.4(95%CI -7.2至8.0),P=0.91。
- 28天和180天全因死亡率无组间效应证据。
- 肾脏替代治疗使用率:碳酸氢钠组109/314(35%)vs 对照组157/313(50%),绝对差异-15.5(95%CI -23.1至-7.8)。
- 其他次要结局(包括不良事件)无组间效应证据。
证据类型、等级与局限
- 证据类型:随机、开放标签临床试验。
- 试验注册号:ClinicalTrials.gov NCT04010630。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对严重代谢性酸血症(pH≤7.20)合并中重度急性肾损伤的ICU患者,静脉碳酸氢钠输注未改变90天全因死亡率。
- 碳酸氢钠组肾脏替代治疗使用率低于对照组(35% vs 50%,绝对差异-15.5%,95%CI -23.1至-7.8)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The effect of sodium bicarbonate infusion on outcome in patients with severe metabolic acidemia and moderate to severe acute kidney injury is unknown.
OBJECTIVE: To determine whether sodium bicarbonate infusion is associated with day 90 all-cause mortality in patients with severe metabolic acidemia and moderate to severe acute kidney injury.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, clinical trial conducted with 640 patients in 43 French intensive care units from October 6, 2019, to December 19, 2023, with 90-day follow-up. The last date of follow-up was June 17, 2024. Adults with severe metabolic acidemia (defined as pH ≤7.20) and moderate to severe acute kidney injury were enrolled.
INTERVENTION: Patients were randomized 1:1 to receive either intravenous sodium bicarbonate infusion or no sodium bicarbonate to target an arterial pH of 7.30 or higher.
MAIN OUTCOMES AND MEASURES: The primary outcome was day 90 all-cause mortality. Secondary outcomes included day 28 and day 180 all-cause mortality; use of organ support therapy, vasopressors, or invasive mechanical ventilation; intensive care unit and hospital length of stay; intensive care unit-acquired infections; fluid balance; day-7 Sequential [Sepsis-related] Organ Failure Assessment score (6 organ systems' function is evaluated and scored from 0 [no dysfunction] to 4 [failure]; total score ranges from 0 [normal] to 24 [maximum failure]); and major adverse kidney events on day 90.
RESULTS: Among 640 randomly assigned patients, 627 were analyzed (313 in the control group and 314 in the bicarbonate group). The median age was 67 years (IQR, 59-74 years); 194 of 314 patients (62%) in the bicarbonate group and 185 of 313 controls (59%) were male. In the primary analysis, day 90 all-cause mortality was 195 of 314 patients (62.1%) in the bicarbonate group and 193 of 313 (61.7%) in the control group (absolute difference, 0.4; 95% CI, -7.2 to 8.0; P = .91). There was no evidence of a group effect on day 28 or day 180 all-cause mortality. Among 18 secondary outcomes, kidney replacement therapy was used in 109 of 314 (35%) bicarbonate group patients and 157 of 313 (50%) controls (absolute difference, -15.5; 95% CI, -23.1 to -7.8). No evidence of a group effect was found on other secondary outcomes, including adverse events.
CONCLUSIONS AND RELEVANCE: For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04010630.
参考来源
- Jung B, Jabaudon M, De Jong A, et al. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial. JAMA. 2025. PMID: 41159812. doi:10.1001/jama.2025.20231
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。